On a corporate action affecting ordinary shares of Intra-Cellular Therapies, Inc. (ITCI)

On January 10, 2025, Intra-Cellular Therapies, Inc. entered into a merger agreement under which it will be acquired by Johnson & Johnson. Intra-Cellular Therapies, Inc. stockholders will receive $132.00 in cash for each share of Intra-Cellular Therapies, Inc. that they own. Transaction is expected to close in 2025 if it is approved by stockholders on the Special Meeting of Stockholders to be held on March 27, 2025. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.